Program
retavibart
Its studies are mostly in Respiratory Syncytial Virus Infections, led by Zhuhai Trinomab Pharmaceutical.
Furthest: phase 3, since Sep 10, 20233 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Zhuhai Trinomab Pharmaceutical | 30 open or running | phase 3since Sep 10, 2023 | Nov 9, 2022 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 9, 2022First study: phase 2 study in Respiratory Syncytial Virus InfectionsFirst studyNCT05630573 · 31 enrolled · China
- Sep 10, 2023Phase 3 study in Respiratory Syncytial Virus InfectionsNCT06083623 · 2,282 enrolled · China
- Nov 26, 2024Phase 3 study in Respiratory Syncytial Virus InfectionsNCT06710925 · 315 enrolled · China
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06710925Respiratory Syncytial Virus Infections · China | 3 | Completed | Jul 27, 2025 | 315 |
| NCT06083623Respiratory Syncytial Virus Infections · China | 3 | Completed | Jun 16, 2025 | 2,282 |
| NCT05630573Respiratory Syncytial Virus Infections · China | 2 | Completed | Jun 30, 2023 | 31 |
How it is read
Names in the registry
- “TNM001”, 3 entries
Conditions, from the studies’ own filings
- Respiratory Syncytial Virus Infections, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.